VistaGen Therapeutics
VTGN
116 hedge funds and large institutions have $168M invested in VistaGen Therapeutics in 2022 Q1 according to their latest regulatory filings, with 19 funds opening new positions, 30 increasing their positions, 37 reducing their positions, and 9 closing their positions.
111% more first-time investments, than exits
New positions opened: 19 | Existing positions closed: 9
9% more funds holding
Funds holding: 106 → 116 (+10)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
3.64% less ownership
Funds ownership: 69.18% → 65.54% (-3.6%)
19% less repeat investments, than reductions
Existing positions increased: 30 | Existing positions reduced: 37
25% less capital inflows, than outflows
Capital inflows: $14.2M | Capital outflows: $18.9M
92% less call options, than puts
Call options by funds: $41K | Put options by funds: $487K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Commodore Capital
New York
|
+$2.37M |
| 2 |
Norges Bank
Oslo,
Norway
|
+$1.92M |
| 3 |
Millennium Management
New York
|
+$1.79M |
| 4 |
Renaissance Technologies
New York
|
+$1.71M |
| 5 |
Sphera Funds Management
Tel Aviv,
Israel
|
+$1.35M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
State Street
Boston,
Massachusetts
|
-$7.25M |
| 2 |
Logos Global Management
San Francisco,
California
|
-$1.45M |
| 3 |
GTC
Ghost Tree Capital
New York
|
-$995K |
| 4 |
Rafferty Asset Management
New York
|
-$956K |
| 5 |
Two Sigma Advisers
New York
|
-$856K |
VTGN Hedge Fund Activity: Q1 2022 in Review
116 of the 6,365 institutional investors tracked by Wall St. Rank reported a position in VistaGen Therapeutics (VTGN) for Q1 2022, worth a combined $168M — down 38% from $269M a quarter earlier.
Buyers outnumbered sellers: 19 funds opened new VTGN positions and 9 closed out — a net gain of 10 holders — while 30 added to existing stakes and 37 trimmed.
The largest buyer was Commodore Capital, adding an estimated $2.37M. The largest seller was State Street, cutting an estimated $7.25M.
- 116 institutional investors held VistaGen Therapeutics (VTGN) as of Q1 2022, up from 106 in Q4 2021.
- Funds reported $168M of VistaGen Therapeutics stock for Q1 2022, down 38% quarter-over-quarter.
- 19 funds opened new VistaGen Therapeutics positions in Q1 2022 and 9 closed out, a net change of +10 holders.
- The largest VistaGen Therapeutics buyer in Q1 2022 was Commodore Capital, an estimated $2.37M added.
- The largest VistaGen Therapeutics seller in Q1 2022 was State Street, an estimated $7.25M sold.
Based on aggregated 13F filings for Q1 2022.